An update on the pharmacotherapy for endometrial cancer

Bibliography

• Ries LAG, Malbert D, Krapcho M, et al. SEER Cancer Statistics review. 1975-2005. Bethesda, MD: National Cancer Institute; 2008 based on November 2007 SEER data submission posted to the SEER web site. Available from: http://seer.cancer.gov/csr/1975_2005/
   Google Scholar
• Karim-Kos HE, de Vries E, Soerjomataram I, et al. Recent trends of cancer in Europe: a combined approach of incidence, survival and mortality for 17 cancer sites since the 1990s. Eur J Cancer 2008;44:1345-89
   PubMed Web of Science ®Google Scholar
• Verdecchia A, Francisci S, Brenner H, et al. Recent cancer survival in Europe: a 2000–02 period analysis of EUROCARE-4 data. Lancet Oncol 2007;8:784-96
   PubMed Web of Science ®Google Scholar
• Bremond A, Bataillard A, Thomas L, et al. Cancer of the endometrium. Br J Cancer 2001;84:31-6
   PubMedGoogle Scholar
• NCCN Clinical Practice Guidelines in Oncology. Uterine neoplasms. Version 1.2013, NCCN.org
   Google Scholar
• Barakat RR, Grigsby PW, Sabbatini P, et al. Corpus: epithelia tumors. In: Hoskins WJ, Perez CA, Young RC, editors. Cancer principles and practice of gynecologic oncology. Lippincott Williams and Wilkins, Philadelphia;2000;10, p. 919-59
   Google Scholar
• Thigpen T, Buchsbaum H, Manfan C, et al. Phase II trial of Adriamycin in the treatment of advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group study. Cancer Treat Rep 1979;63:21-7
   PubMedGoogle Scholar
• Thigpen T, Blessing J, Homesley H, et al. Phase II trial of cisplatin as first line chemotherapy in patients with advanced or recurrent endometrial carcinoma:a Gynecologic Oncology Group study. Gynecol Oncol 1989;33:68-70
   PubMed Web of Science ®Google Scholar
• Ball H, Blessing J, Lentz S, et al. A phase II trial of taxol in advanced and recurrent adenocarcinoma of the endometrium: aGynecologic Oncology Group study. Gynecol Oncol 1996;62:278
   PubMed Web of Science ®Google Scholar
• Humber CE, Tierney JF, Symonds RP, et al. Chemotherapy for advanced, recurrent or metastatic endometrial cancer: a systemic review of Cochrane collaboration. Ann Oncol 2007;18:409-20
   PubMed Web of Science ®Google Scholar
• Thigpen JT, Blessing JA, DiSaia PJ, et al. A randomized comparison of doxorubicin alone versus doxorubicin plus cyclophosphamide in the management of advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group study. J Clin Oncol 1994;12:1408-14
   PubMed Web of Science ®Google Scholar
• Thigpen JT, Brady MF, Homesley HD, et al. Phase III trial of doxorubicin with or without cisplatin in advanced endometrial carcinoma: a Gynecologic Oncology Group study. J Clin Oncol 2004;22:3902-8
   PubMed Web of Science ®Google Scholar
• Fleming GF, Filiaci VL, Bentley RC, et al. Phase III randomized trial of doxorubicin plus cisplatin versus doxorubicin plus 24-h paclitaxel + filgrastim in endometrial carcinoma: a Gynecologic Oncology Group study. Ann Oncol 2004;5:1173-8
   Google Scholar
• Fleming GF, Brunetto VL, Cella D, et al. Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol 2004;22:2159-66
   PubMed Web of Science ®Google Scholar
• Gallion HH, Brunett VL, Cibull M, et al. Randomized phase III trial of standard timed doxorubicin plus cisplatin versus circadian timed doxorubicin plus cisplatin in stage III and IV or recurrent endometrial carcinoma: a Gynecologic Oncology Group study. J Clin Oncol 2003;21:3808-13
   PubMed Web of Science ®Google Scholar
• Long HJ, Nelimark RA, Podratz KC, et al. Phase III comparison of methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) vs. doxorubicin and cisplatin (AC) in women advanced primary or recurrent metastatic carcinoma of the uterine endometrium. Gynecol Oncol 2006;100:501-5
   PubMed Web of Science ®Google Scholar
• Gadducci A, Cosio S, Genazzani AR. Old and new perspectives in the pharmacological treatment of advanced or recurrent endometrial cancer: hormonal therapy, chemotherapy and molecularly targeted terapie. Crit Rev Oncol Hematol 2006;58:242-56
   PubMed Web of Science ®Google Scholar
• Trope C, Kristensen G. Current status of chemotherapy in gynaecologic cancer. Semin Oncol 1997;24:S15-22
   Web of Science ®Google Scholar
• Briet JM, Hollema H, Reesink N, et al. Lymphvascular space involvement: an independent prognostic factor in endometrial cancer. Gynecol Oncol 2005;96:799-804
   PubMed Web of Science ®Google Scholar
• Randall ME, Filiaci VL, Muss H, et al. Randomised phase III trial of whole abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: a Gynecologic Oncology Group study. J Clin Oncol 2006;24:36-44
   PubMed Web of Science ®Google Scholar
• Hogberg T, Rosemberg P, Kristensen G, et al. A randomized phase III study on adjuvant treatment with radiation (RT)+chemotherapy (CT) in early-stage high-risk endometrial cancer (b NSGO-EC-9501/EORTC 55991). J Clin Oncol 2007;25:18(Suppl); abstract 5503
   Google Scholar
• Hogberg T, Signorelli M, de Oliveira CF, et al. Sequential adjuvant chemotherapy and radiotherapy in endometrial cancer–results from two randomised studies. Eur J Cancer 2010;46:2422-31
   PubMed Web of Science ®Google Scholar
• Maggi R, Lissoni A, Spina F, et al. Adjuvant chemotherapy vs. radiotherapy in high-risk endometrial carcinoma: results of a randomized trial. Br J Cancer 2006;95:266-71
   PubMed Web of Science ®Google Scholar
• Susumu N, Sagae S, Udagawa Y, et al. Randomized phase III trial of pelvic radiotherapy versus cisplatin-based combined chemotherapy in patients with intermediate- and high-risk endometrial cancer: a Japanese Gynecologic Oncology Group study. Gynecol Oncol 2008;108:226-33
   PubMed Web of Science ®Google Scholar
• Homesley H, Filiaci V, Gibbons S, et al. Randomized phase III trial in advanced endometrial carcinoma of surgery and volume-directed radiation followed by cisplatin and doxorubicin with or without paclitaxel: a Gynecologic Oncology Group study. Gynecol Oncol 2008;108:S2
   Web of Science ®Google Scholar
• du Bois A, Quinn M, Thigpen T, et al. 2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004). Ann Oncol 2005;16(Suppl 8):viii7-viii11
   PubMed Web of Science ®Google Scholar
• Price FV, Edwards RP, Kelley JL, et al. A trial of outpatient paclitaxel and carboplatin for advanced, recurrent, and histologic high-risk endometrial carcinoma: preliminary report. Semin Oncol 1997;24(5 Suppl 15):S15-S78-S15-82
   Web of Science ®Google Scholar
• Dimopoulos MA, Papadimitriou CA, et al. Paclitaxel and cisplatin in advanced or recurrent carcinoma of the endometrium: long-term results of a phase II multicenter study. Gunecol oncol 2000;78(1):52-7
   PubMed Web of Science ®Google Scholar
• Miller D, Filiaci V, Fleming G, et al. Randomized phase III noninferiority trial of first line chemotherapy for metastatic or recurrent endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 2012;125:771
   Web of Science ®Google Scholar
• Kelley RM, Baker WH. Progestational agents in the treatment of carcinoma of the endometrium. N Engl J Med 1961;264:216-22
   PubMed Web of Science ®Google Scholar
• Kesterson JP, Fanning J. Fertility-sparing treatment of endometrial cancer: options, outcomes and pitfalls. J Gynecol Oncol 2012;23:120-4
   PubMed Web of Science ®Google Scholar
• Kalogiannidis I, Agorastos T. Conservative management of young patients with endometrial higly-differentiated adenocarcinoma. J Obstet Gynecol 2011;31:13-17
   PubMedGoogle Scholar
• Gallos ID, Yap J, Rajkhowa M, et al. Regression, relapse, and live birth rates with fertility-sparing therapy for endometrial cancer and atypical complex endometrial hyperplasia: a systematic review and metaanalysis. Am J Obstet Gynecol 2012;207:266 e I-266 e 12
   Web of Science ®Google Scholar
• Yamazawa K, Hirai M, Fujito A, et al. Fertility.preserving treatment with progestin, and pathological criteria to predict responses, in young women with endometrial cancer. Hum Reprod 2007;22:1953-8
   PubMed Web of Science ®Google Scholar
• Mazzon I, Corrado G, Masciullo V, et al. Conservative surgical management of stage IA endometrial carcinoma for fertility preservation. Fertil Steril 2010;93:1286-9
   PubMed Web of Science ®Google Scholar
• Baker J, Obermair A, Gebski V. Efficacy of oral or intrauterine device-delivered progestin in patients with complex endometrial hyperplasia with atypia or early endometrial adenocarcinoma: a meta-analysis and systematic review of the literature. Gynecol Oncol 2012;125(1):263-70
   PubMed Web of Science ®Google Scholar
• Park JY, Kim DY, Kim JH, et al. Long-term oncologic outcomes after fertility-sparing management using oral progestin for young women with endometrial cancer (KGOG 2002). Eur J Cancer 2013;49(4):868-74
   PubMed Web of Science ®Google Scholar
• Park JY, Lee SH, Seong SJ, et al. Progestin re-treatment in patients with recurrent endometrial adenocarcinoma after successful fertility-sparing management using progestin. Gynecol Oncol 2013;129(1):7-11
   PubMed Web of Science ®Google Scholar
• Gallup DG, Stock RJ. Adenocarcinoma of the endometrium in women 40 years of age or younger. Obstet Gynecol 1984;64:417-20
   PubMed Web of Science ®Google Scholar
• Markmann M. Hormonal therapy of endometrial cancer. Eur J Cancer 2005;41:673-5
   PubMed Web of Science ®Google Scholar
• Kauppila A. Progestin therapy of endometrial, breast and ovarian carcinoma. A review of clinical observations. Acta obstet Gynecol Scan 1984;63:441-50
   PubMed Web of Science ®Google Scholar
• Thigpen JT, Brady MF, Alvarez RD, et al. Oral medroxyprogesterone acetate in the treatment of advanced or recurrent endometrial carcinoma: a dose-response study by the Gynecologic Oncology Group. J Clin Oncol 1999;17:1736-44
   PubMed Web of Science ®Google Scholar
• Thigpen JT, Brady MF, Alvarez RD, et al. Oral medroxyprogesterone acetatein the treatment of advanced or recurrent endometrial carcinoma: a dose-response study by the Gynecologic Oncology Group. J Clin Oncol 1999;17:1736-44
   PubMed Web of Science ®Google Scholar
• Thigpen T, Brady MF, Homesley HD, et al. Tamoxifen in the treatment of advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group study. J Clin Oncol 2001;19:364-7
   PubMed Web of Science ®Google Scholar
• Florica J, Brunetto P, Hanjani S, et al. A phase II study (GOG)153 of recurrent and advanced endometrial carcinoma treated with alternating courses of megestrol acetate and tamoxifen citrate. Proc ASCO 2000;19:379a
   Google Scholar
• Kokka F, Brockbank E, Oram D, et al. Hormonal therapy in advanced or recurrent endometrial cabcer. Cochrane Database Syst Rev 2010;12
   PubMed Web of Science ®Google Scholar
• Dizon DS, Blessing JA, McMeekin S, et al. Phase II Trial of Ixabepilone as second-line treatment in advanced endometrial cancer:gynecologic oncology group trial 129-P. J Clin Oncol 2009;27:3104-8
   PubMed Web of Science ®Google Scholar
• Cancer Genome Atlas Research Network. Kandoth C, Schultz N, et al. Integrated genomic characterization of endometrial carcinoma. Nature 2013;2(497):67-73
   Google Scholar